Back to top

Replimune downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Replimune (REPL) to Underweight from Neutral without a price target The regulatory path forward for RP1 is unclear and potentia...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Replimune Group, Inc. (REPL)